How to buy InVivo Therapeutics stock

InVivo Therapeutics Holdings Corp is a biotechnology business based in the US. InVivo Therapeutics shares (NVIV) are listed on the NASDAQ and all prices are listed in US Dollars. InVivo Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of 0.00.

InVivo Therapeutics share price

Use our graph to track the performance of NVIV stocks over time.

InVivo Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$0.50 - $2.55
50-day moving average	$0.98
200-day moving average	$0.97
Wall St. target price	$37.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.30

Buy InVivo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy InVivo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of InVivo Therapeutics Holdings Corp by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InVivo Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-36.41%
Return on equity TTM	-73.27%
Profit margin	0%
Book value	$0.81
Market capitalisation	$26.2 million

TTM: trailing 12 months

Shorting InVivo Therapeutics shares

There are currently 4.9 million InVivo Therapeutics shares held short by investors – that's known as InVivo Therapeutics's "short interest". This figure is 11.9% up from 4.4 million last month.

There are a few different ways that this level of interest in shorting InVivo Therapeutics shares can be evaluated.

InVivo Therapeutics's "short interest ratio" (SIR)

InVivo Therapeutics's "short interest ratio" (SIR) is the quantity of InVivo Therapeutics shares currently shorted divided by the average quantity of InVivo Therapeutics shares traded daily (recently around 2.7 million). InVivo Therapeutics's SIR currently stands at 1.84. In other words for every 100,000 InVivo Therapeutics shares traded daily on the market, roughly 1840 shares are currently held short.

However InVivo Therapeutics's short interest can also be evaluated against the total number of InVivo Therapeutics shares, or, against the total number of tradable InVivo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InVivo Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 InVivo Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1449% of the tradable shares (for every 100,000 tradable InVivo Therapeutics shares, roughly 145 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InVivo Therapeutics.

Find out more about how you can short InVivo Therapeutics stock.

InVivo Therapeutics share dividends

We're not expecting InVivo Therapeutics to pay a dividend over the next 12 months.

Have InVivo Therapeutics's shares ever split?

InVivo Therapeutics's shares were split on a 1:30 basis on 11 February 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InVivo Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for InVivo Therapeutics shares which in turn could have impacted InVivo Therapeutics's share price.

InVivo Therapeutics share price volatility

Over the last 12 months, InVivo Therapeutics's shares have ranged in value from as little as $0.5 up to $2.55. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InVivo Therapeutics's is 1.4429. This would suggest that InVivo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

InVivo Therapeutics overview

InVivo Therapeutics Holdings Corp. , a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

• What percentage of InVivo Therapeutics is owned by insiders or institutions?

  Currently 2.174% of InVivo Therapeutics shares are held by insiders and 6.924% by institutions.

• How many people work for InVivo Therapeutics?

  Latest data suggests 6 work at InVivo Therapeutics.

• When does the fiscal year end for InVivo Therapeutics?

  InVivo Therapeutics's fiscal year ends in December.

• Where is InVivo Therapeutics based?

  InVivo Therapeutics's address is: One Kendall Square, Cambridge, MA, United States, 02139

• What is InVivo Therapeutics's ISIN number?

  InVivo Therapeutics's international securities identification number is: US46186M5067

• What is InVivo Therapeutics's CUSIP number?

  InVivo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 46186M100